查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1725960

前糖尿病市场:现状分析及预测(2025年～2033年)

Prediabetes Market: Current Analysis and Forecast (2025-2033)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

糖尿病前期是指患者出现类似糖尿病的症状，例如血糖值高于正常范围但低于第2型糖尿病的诊断阈值。根据美国糖尿病协会 (ADA) 的定义，糖尿病前期是指糖化血红蛋白 (A1C) 检测结果在 5.7% 至 6.4% 之间的疾病。糖尿病前期会导致血糖耐受性差或胰岛素敏感性降低，可能导致糖尿病、心臟病和中风。糖尿病前期可能没有明显的症状，因此可能在数年内都难以察觉，需要定期检查。糖尿病前期的症状包括肥胖、缺乏运动、不良饮食、遗传因素和老化。因此，健康的糖尿病前期饮食、规律的体能活动和减重有助于预防糖尿病，尤其是在确诊糖尿病前期之后。

预计在预测期内（2025-2033），糖尿病前期市场规模将以约10.02%的速度成长。由于糖尿病前期盛行率的上升、人们对该疾病认识的不断提高以及全球预防医学趋势的变化，糖尿病前期市场正在显着发展。久坐的生活方式、不合理的饮食和日益增长的肥胖是导致糖尿病前期患病率上升的新因素，尤其是在城市地区。越来越多的人意识到，未经治疗的糖尿病前期会导致危险的后果，例如发展为第2型糖尿病和心血管疾病，这鼓励患者采取早期干预策略。此外，频繁的健康检查和改善生活方式是政府和其他医疗相关机构持续鼓励的两个方面，推动市场的成长。

按产品类型划分，市场细分为诊断和设备、药品和治疗剂、营养补充剂和功能性食品以及其他。其中，诊断和设备领域占据最高的市场占有率。这种主导地位源于糖尿病早期检测工具的不断增多，人们对糖尿病前期药物治疗和管理意识的不断提升，以及血糖监测仪、糖化血红蛋白 (HbA1c) 检测试剂盒和连续血糖监测 (CGM) 设备的日益普及。然而，由于人们转向使用天然保健解决方案，以及使用营养保健食品和功能性食品来控制血糖，预计未来几年营养保健食品和功能性食品领域将以最快的速度成长。

依年龄段，市场分为儿童、成人和老年人。其中，成人市场占有最大的市场占有率。这是因为成年人口久坐不动、食用不健康食品且压力水平较高，增加了患糖尿病前期的风险。然而，老年人口市场成长最快。由于年龄是糖耐量受损和胰岛素抗性的常见预测指标，预计全球老年人口的增长将推动糖尿病前期治疗的发展。

根据最终用户，全球市场细分为医院和诊所、诊断中心、家庭护理机构和其他。其中，医院和诊所占据最大的市场占有率。主要因素包括患者就诊量增加、设备齐全的诊断实验室的普及以及擅长早期发现和控製糖尿病前期的医疗保健从业人员的增多。然而，预计未来家庭医疗保健领域将呈现最高的复合年增长率。这得益于个人健康监测设备的使用增加、预防医学知识的普及以及远距医疗和远端患者监测设施的发展。

为了更了解糖尿病前期治疗方案的市场采用情况，我们根据北美（美国、加拿大等）、欧洲（德国、英国、法国、西班牙、义大利等）、亚太地区（中国、日本、印度等）和世界其他地区的全球采用情况对市场进行了分析。其中，北美由于其高发病率、完善的医疗基础设施以及政府大力推广早期筛检和预防医学的举措，占据了主要的市场占有率。然而，由于快速的城市化、肥胖率的上升、生活方式的改变以及医疗保健投资的增加，亚太地区的糖尿病前期市场正在蓬勃发展。

推动市场发展的主要公司包括Abbott Laboratories，F． Hoffmann-La Roche Ltd.，Siemens Healthineers，Ascensia Diabetes Care，Omada Health，Noom, Inc.，Eli Lilly and Company，PharmaLinea，Oramed，Bayer 有AG等。

本报告提供全球前糖尿病市场相关调查，市场概要，以及各产品类型，各年龄层，各终端用户，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 市场简介

第2章 调查手法或假设

第3章 摘要整理

第4章 市场动态

  • 促进因素
  • 机会
  • 阻碍因素
  • 趋势
  • PESTEL分析
  • 需求面分析
  • 供给方面分析

第5章 价格分析

  • 地区价格分析
  • 价格的影响因素

第6章 全球前糖尿病市场收益(100万美元)，2023年～2033年预测

第7章 各产品类型市场分析

  • 诊断及设备
  • 医药品及治疗药
  • 营养补充品和机能性食品
  • 其他

第8章 各年龄层市场分析

  • 儿童
  • 大人
  • 老年人

第9章 各终端用户市场分析

  • 医院·诊疗所
  • 诊断中心
  • 居家照护
  • 其他

第10章 各地区市场分析

  • 北美
    • 美国
    • 加拿大
    • 其他
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他
  • 其他的国家

第11章 价值链分析

  • 限制分析
  • 市场参与企业清单

第12章 竞争情形

  • 竞争仪表板
  • 竞争的市场定位分析
  • 波特五力分析

第13章 企业简介

  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthineers
  • Ascensia Diabetes Care
  • Omada Health
  • Noom, Inc.
  • Eli Lilly and Company
  • PharmaLinea
  • Oramed
  • Bayer AG

第14章 缩写与假设

第15章 附录

简介目录
Product Code: UMHE213267

Prediabetes is a diabetes-like condition in which the prediabetes symptoms include a blood glucose level that is above the normal range but below the thresholds considered indicative of type 2 diabetes. According to the American Diabetes Association (ADA), glycated hemoglobin (A1C) test results between 5.7% and 6.4% come in the prediabetes range. Prediabetes points to poor outcomes of glucose tolerance or even insulin sensitivity, which can lead to the development of diabetes, heart conditions, and stroke. Prediabetes can have no visible signs, and, therefore, individuals may be unaware of the condition for several years and require frequent checkups. Some of the signs of prediabetes are obesity, lack of physical activity, poor diet, heredity, and increasing age. Thus, a healthy prediabetes diet, regular physical activity, and weight loss may help to prevent the development of diabetes, specifically if one has been diagnosed with prediabetes.

The Prediabetes market is set to show a growth rate of about 10.02% during the forecast period (2025-2033F). The prediabetes market is significantly progressing because of the increasing rates of its prevalence, the augmentation of awareness about the disease, and the changing trends in the global focus on preventive medicine. A sedentary lifestyle, improper diet, and increased prevalence of obesity have been emerging factors for the rise in the incidence of prediabetes, primarily in urban communities. Growing awareness of the risky consequences of untreated prediabetes, such as the development of type 2 diabetes and cardiovascular diseases, is driving early intervention strategies among patients. Moreover, frequent physical checkups and modifications in lifestyle represent two aspects that governments and other healthcare-related bodies are continuously encouraging, thus driving the market growth.

Based on product type, the market is segmented into diagnostics & devices, pharmaceuticals & therapeutics, nutraceutical & functional foods, and others. Among these, the diagnostics & devices segment has the highest market share. This dominance is due to the growing number of tools for early detection of diabetes, heightened consciousness among people about prediabetes medications and management, and the increased use of blood glucose monitors, HbA1c testing kits, and CGM devices. However, the nutraceuticals & functional foods sector is expected to grow at the fastest rate in the future, due to the shift towards using natural healthcare solutions, and the use of dietary supplements and functional foods to control blood sugar levels.

Based on the age group category, the market is segmented into children, adults, and the elderly. Out of these, the adult segment has the biggest market share. This is because the adult population is engaged in sedentary lifestyles, consumes unhealthy foods, and experiences increased stress levels, which increases the risk of prediabetes. However, the fastest-growing segment is expected to be the elderly segment. Since age is a common predictor of glucose intolerance and insulin resistance, prediabetes treatment is expected to stem from the growing geriatric population across the globe.

Based on the end-user category, the global market is categorized into hospitals & clinics, diagnostic centers, homecare settings, and others. Among these, the hospitals & clinics segment has the largest market share. Major factors are increased patients' visits to hospitals, availability of enhanced diagnostic laboratories, and healthcare practitioners' specialization in early identification and control of prediabetes. However, the Homecare Settings segment is expected to show the highest CAGR in the future. This is due to the increase in the use of personal health monitoring devices, knowledge of preventive care, and developments in telemedicine and remote patient monitoring facilities.

For a better understanding of the market adoption of therapeutics solutions for prediabetes, the market is analyzed based on its worldwide adoption in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Among these, the North America region holds a significant market share due to its high disease prevalence, well-established healthcare infrastructure, and strong government initiatives promoting early screening and preventive care. However, the Asia-Pacific Prediabetes market is moving forward due to rapid urbanization, increasing obesity rates, changing lifestyles, and growing healthcare investments.

Some major players running in the market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Ascensia Diabetes Care, Omada Health, Noom, Inc., Eli Lilly and Company, PharmaLinea, Oramed, and Bayer AG.

TABLE OF CONTENTS

1.Market Introduction

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.Research Methodology or Assumption

  • 2.1. Research Process of the Global Prediabetes Market
  • 2.2. Research Methodology of the Global Prediabetes Market
  • 2.3. Respondent Profile

3.Executive Summary

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.Market Dynamics

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Collaboration & Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.Pricing Analysis

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.Global Prediabetes Market Revenue (USD Mn), 2023-2033F

7.Market Insights By Product Type

  • 7.1. Diagnostics & Devices
  • 7.2. Pharmaceuticals & Therapeutics
  • 7.3. Nutraceuticals & Functional Foods
  • 7.4. Others

8.Market Insights By Age Group

  • 8.1. Children
  • 8.2. Adults
  • 8.3. Elderly

9.Market Insights By End User

  • 9.1. Hospitals & Clinics
  • 9.2. Diagnostic Centers
  • 9.3. Homecare Settings
  • 9.4. Others

10.Market Insights By Region

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11.Value Chain Analysis

  • 11.1. Marginal Analysis
  • 11.2. List of Market Participants

12.Competitive Landscape

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.Company Profiled

  • 13.1. Abbott Laboratories
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Roche Diagnostics
  • 13.3. Siemens Healthineers
  • 13.4. Ascensia Diabetes Care
  • 13.5. Omada Health
  • 13.6. Noom, Inc.
  • 13.7. Eli Lilly and Company
  • 13.8. PharmaLinea
  • 13.9. Oramed
  • 13.10. Bayer AG

14.Acronyms & Assumption

15.Annexure